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ABSTRACT 
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system 
tumor, with median survival after diagnosis of less than 12 months because 
dissemination into the brain parenchyma limits the long-term effectiveness of 
surgical resection, and because GBM cells are resistant to radiation and 
chemotherapy. This sad dismal prognosis for patients with GBM emphasizes the 
need for greater understand of the fundamental biology of the disease. 
Invasion is one of the major causes of treatment failure and death from glioma, 
because disseminated tumor cells provide the seeds for tumor recurrence. 
Inflammation is increasingly recognized as an important component of invasion. 
In the brain, inflammation can occur by activation of microglia, the resident 
macrophages of the brain, or by tumor-associated blood macrophages. 
Therefore, we hypothesize that activity of the innate immune system in the brain 
can influence tumor progression by secreting cytokines such as Tumor Necrosis 
Factor alpha (TNF-α). In this study, we show that patient-derived glioma spheres 
undergo morphological changes in response to TNF-α that are associated with 
changes in migration behavior in vitro. These morphological changes include 
appearance of tumor islands in site different from where the primary tumor cells 
were seeded. We further showed that TNF-α treated cells significantly increased 
expression of cell adhesion molecules such as CD44 and VCAM-1. Furthermore, 
we demonstrate increased cell density also caused increased in expression of 
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cell adhesion molecules. The extent to which these are recapitulated in vivo will 
be investigated. 
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CHAPTER ONE 
INTRODUCTION AND BACKGROUND INFORMATION 
 
Introduction 
Glioblastoma multiforme (GBM) is the most lethal primary tumor of the central 
nervous system (CNS), with median post-diagnosis survival of less than 12 
months [1, 2]. The dismal prognosis of GBM patients necessitates achieving a 
better understanding of the fundamental biology of this disease.  
The invasive nature of GBM plays a major role in treatment failure and death, 
such that disseminated glioma cells provide the seeds for tumor recurrence. 
Inflammation is increasingly recognized as a central factor of brain responses to 
brain tumors; inflammatory cells are important components of the tumor 
microenvironment, promoting tumor survival and migration [3]. Inflammatory 
responses in the brain can occur by activation of either microglia (the resident 
macrophages of the brain), or tumor-associated macrophages.  Previous studies 
show that certain innate immune system-associated signaling molecules and 
their receptors have been co-opted by tumor cells for invasion. Tumor Necrosis 
Factor-alpha (TNF-α) and its receptor (TNFR1 and TNFR2) are examples of such 
molecules [3].  
The aim of the present study is to investigate the role of TNF-α on patient-derived 
GBM cells. Our preliminary data show a trend of morphological changes in GBM 
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cells following in vitro TNF-α treatment. Further analysis shows that these 
morphological changes are associated with alterations in GBM cells’ migratory 
behavior. Another significant observation of this study reveals up-regulation of 
different cell surface molecules on GBM cells as a downstream effect of TNF-α. 
VCAM-1 and CD44 in particular are among these cell adhesion and receptors 
molecules examined in the present study (Mahadev et al., submitted).  
Furthermore, decreased expression of Ki67 in TNF-α treated GBM cells indicate 
effects of TNF-α on proliferation.  
Moreover, our results provide evidence suggesting the potential role of the 
density of cultured cells in initiation of GBM cell invasion; this is based on the 
observation of the positive correlation between Ki67 expression and cell density, 
independently of TNF-α. The extent to which these mechanisms are active in 
vivo will be subject to future investigation. Besides, our observations demonstrate 
the possible role of cell density in and the formation of secondary islands, 
emphasizing on the effects of increased cell-cell adhesion in secretion of different 
cytokines. 
 
Background 
The term "glioma" refers to tumors that exhibit histological features similar to 
those of normal glial cells (astrocytes, oligodendrocytes) and ependymal cells. 
Astrocytomas account for 80–85% of all gliomas. The World Health Organization 
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(WHO) classifies glioma into four different grades, counting grade IV glioma, also 
called GBM, as the most aggressive and grade I glioma as the least aggressive 
type.  
Unfortunately, despite major breakthroughs in cancer research, the prognosis of 
malignant glioma patients remains dismal, owing to traits distinct to GBM. The 
main characteristics of gliomas responsible for their lethality and inefficacy of 
most treatments include their ability to diffuse and infiltrate throughout the brain 
parenchyma, their robust angiogenesis, which is consequent of their invasive 
behavior and their intense resistance to apoptosis, as well as their genomic 
instability [4, 5].  
Different factors could cause heterogeneity of GBM. Initially it was believed that 
genetic chaos is the main source of GBM heterogeneity.  Further studies have 
also attributed heterogeneity to diversity in the tumor microenvironment which 
could cause development of different cell types (described in Figure 2) [4]. There 
is growing evidence suggesting that rather than being simple bystanders, 
different tumor cell populations are capable of establishing a complex network of 
interactions between each other and within the tumor microenvironment, which 
supports tumor growth by establishing a glioma niche over time [6].   
For many years the relationship between tumor cells and tumor 
microenvironment has been modeled as the relationship between the seed and 
soil, since soil can have significant effects on the growth of the seed. The effects 
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of tumor microenvironment on tumor progression have been emphasized in 
almost all kinds of tumors, including glioma [7]. Microglia, as a part of the innate 
immune system, are involved in creation of the tumor microenvironment, thereby 
influencing tumor angiogenesis and invasion. They are the resident 
macrophages in brain tissue and are important contributors to tumor progression 
[7]. They contribute substantially to the tumor mass of glioma. They stay in a 
quiescent stage under normal brain conditions. Upon activation, stimulated by 
brain injury or tumor formation, microglia initiate inflammatory pathways and 
secrete different cytokines. Interestingly, tumor cells have the ability to co-opt 
microglia secreted cytokines in their own favor, and use them in their growth and 
invasion [8]. TNF-α is an important example of cytokine secreted by activated 
microglia. The objective of the present study is to investigate the effect of 
activated-microglia-secreted pro-inflammatory cytokines, such as TNF-α, on 
glioma cells’ invasive behavior. To that end, the morphological effects of TNF-α 
on patient derived GBM cells as well as its effects on cell proliferation and cell 
adhesion molecules including Ki67, VCAM and CD44 as a cell-cell interaction 
marker were studied. 
Heterogeneity Maintenance in Glioblastoma 
As is mentioned, GBM is defined by different characteristics; each of them alone 
or in combination could be a potential cause of the high mortality rate in this 
disease. Among these characteristics is its striking cellular heterogeneity [9]. Due 
 to this inherent trait, a single tumor mass within one patient consists of population 
of cells with different biolog
bulk typically consists of Tumor Initiating Cells (TIC), the tumor cells, microglia as 
a part of the innate immune system, and different cytokines secreted into the 
tumor microenvironment during the infla
promote the therapeutic resistance and tumor angiogenesis
seeds for tumor invasion and its dissemination through the brain parenchyma
 
 
Figure 1. GBM tumor core and invasive cells in the context of cells found in the brain 
parenchyma. Invasive glioblastoma multiforme cells (dark nuclei) secrete various autocrine 
motility factors that support the process of invasion. Cells in the central nervous system (CNS) 
express cognate receptors for ligands secreted by GBM cells, which enable commun
between glioblastoma multiforme cells and the normal cells in the path of invasion (reproduced 
from [12]).  
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ical features. As shown in Figure 1, a single tumor 
mmatory response [9]. TICs, known to 
 [10, 11
 
], provides the 
. 
ication 
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Innate Immune System.  
Similar to other systemic organs, the central nervous system (CNS), promotes a 
critical immune response against pathogens and cell debris [13]. In the brain this 
response is developed by innate immune system based upon the activation of 
the resident microglial cells. An evidence for that is the infiltration of T-
lymphocytes and antigen presenting cells (APC) during a variety of CNS 
pathologies, such as multiple sclerosis and glioma [13]. In addition to resident 
APCs and macrophages, microglia are also key players in coordinating this 
system of active surveillance [14]. 
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Figure 2. Heterogeneity origins and maintenance. A, according to clonal evolution, 
heterogeneity is caused by the acquisition of mutations and expansion. Upon a selective 
pressure, such as drug treatment, more adapted clones survive and, through consequent 
mutations, give rise again to a heterogeneous population. B, the CSC model postulates that only 
CSCs are able to divide indefinitely, giving rise to cells that will differentiate heterogeneously. 
CSCs can also acquire mutations and generate a heterogeneous CSC population. CSCs are 
considered to be drug resistant, such that surviving cells serve as a reservoir for tumor relapse. 
C, whether heterogeneity arises by clonal evolution, CSCs, or CSCs undergoing clonal evolution, 
its maintenance requires interactions between CSCs and/or tumor cells and their 
microenvironment and between different CSCs and/or tumor cell clones. Those interactions can 
drive an increase in tumor growth, drug resistance, immune suppression, angiogenesis, invasion, 
or even CSC renewal (reproduced from [4]). 
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Through intimate relationships with the surrounding microenvironment, microglia 
maintain a quiescent phenotype in the normal CNS. In the context of CNS insult 
or injury, microglia convert to an active phenotype, with increased 
proliferation, motility, phagocytic activity, and the release of cytokines and 
reactive oxygen species. Activated APCs and microglia have similar roles to 
macrophages in peripheral tissues, serving as essential components of both the 
innate and adaptive immune responses. In addition to lymphocytes, microglia 
have also been found in CNS disease processes, including tumors of the CNS 
[14, 15]. 
One of the characteristic features of microglia is their rapid activation in response 
to injury, inflammation, infection, and brain tumors [16]. Microglia are an 
abundant portion of the CNS cell population, comprising 5% to 20% of the total 
glial cell population, and in normal brain are as numerous as neurons [14]. 
Activated microglia in CNS mediate inflammatory responses which are an 
important property of brain pathology and cancer. During inflammation, microglia 
secrete different cytokines and chemokines which can be co-opted by different 
tumor cells. In regards to the brain, it remains controversial whether the 
inflammatory response elicited by microglial cells are beneficial or detrimental to 
various tumors’ survival. The chronic activation of microglia may cause neuronal 
damage through the release of potentially cytotoxic molecules such as 
proinflammatory cytokines, reactive oxygen intermediates, proteinases and 
complement proteins. On the other hand, in a variety of CNS pathologies, such 
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as infection, injury, and neurodegenerative disease, [WHAT??] cause the 
activation of the resting ramified microglia by detecting proinflammatory 
cytokines. Therefore, suppression of microglia-mediated inflammation has been 
considered as an important strategy in neurodegenerative disease therapy [17]. 
For example, activated microglia express Toll-Like Receptors (TLRs) and initiate 
innate inflammatory responses through secretion of cytokines, chemokines and 
nitric oxide (NO). Cytokines released by activated microglia that are in the scope 
of this study include interleukin (IL)-1, IL-6 and TNF-α [14]. 
 
Tumor Necrosis Factor α (TNF-α) 
Human TNF-α is a trans-membrane protein, composed of 233 amino acids, of 
which 35 amino acids form its cytoplasmic domain, 21 amino acids its 
transmembrane segment, and 177 amino acids its extracellular domain (ECD). 
The soluble form of this protein is produced by the matrix metalloproteinase TNF-
α converting enzyme (TACE), which is responsible for cleaving TNF-α from the 
membrane and producing the soluble form of TNF-α. TNF-α was first identified in 
the late 1970’s as a potent pro-inflammatory and immune-modulatory cytokine, 
implicated in inflammatory conditions such as cancer [18]. Since the TNF-α gene 
was cloned in 1984, extensive research has revealed a variety of roles for TNF-α 
under physiological and pathological conditions; some examples of such roles 
include immunity under physiological conditions and inflammation under 
 pathological conditions. TNF
as microglia cells. Interestingly
from the membrane of the activated 
On the cellular level, TNF
distinct signaling pathways. 
eventually NF-κB pathways resulting in expression of VCAM
ezrin, radixin and moesi
increased expression of hyaluronan, 
20]. 
 
 Figure 3. Downstream effects of TNF
10 
-α is produced by macrophages and T
, TNF-α, as well as IL-1, stimulates 
microglia cells.  
-α exerts its effects through its receptors to activate 
These signaling pathways include the 
-1 as well as the 
n (ERM) phosphorylation and interaction with CD44 
a major extracellular matrix component 
-α in the regulation of VCAM-1 and CD44 
-cells as well 
its own release 
PI3K and 
and 
[19, 
 
expression. 
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TNF-α and VCAM-1 
VCAM-1, or cluster of differentiation 106 (CD106), is a cell surface protein 
expressed by macrophages and activated endothelial cells. It is a member of the 
immunoglobulin superfamily. Activation of the receptors for TNF-α on target cells 
such as endothelium mediates the upregulation of cell adhesion molecules 
including VCAM-1, leading to leukocyte migration and accumulation at the site of 
inflammation. VCAM-1 is a ligand to leukocyte integrin VLA-4 and is thought to 
cooperate with CD44 in cell migration [21, 22] . The schematic in Figure 3 shows 
the downstream effects of TNF-α in the regulation of VCAM-1 expression.  
As shown, the function of TNF-α is caused by several signal transduction 
pathways that are activated by the interaction of TNF-α with TNF receptor 1 and 
receptor 2 (TNFR-1, TNFR-2) [23]. Activation of these receptors trigger 
intracellular signaling cascade which leads to PI 3-kinase (PI3K) activation and 
subsequent Akt phosphorylation. The activated Akt will in turn activate NF-κB as 
well as MAPK signaling cascades. One of the targets for these signaling 
cascades is transcription of VCAM-1, a major endothelial ligand increasing cell 
adhesion. Therefore, activation of MAPK and NF-κB will ultimately result in 
VCAM-1 gene expression and protein production [5, 23-27].    
TNF-α and CD44 
The underlying molecular mechanisms of GBM invasion are complex and involve 
integrated biochemical processes requiring a coordinated effort of intracellular 
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and extracellular interactions. For effective invasion, tumor cells must first detach 
from the nascent tumor mass and invade the surrounding stroma, which is 
composed of parenchymal cells and Extra Cellular Matrix (ECM). One 
downstream effect of activated microglia- released cytokines, including IL-1α, IL-
6 or TNF-α, is increased expression of cell adhesion molecules (CAM). To 
illustrate, the presence of these cytokines near blood vessels stimulates the 
endothelial cells, thereby, cause increased expression of cell adhesion molecules 
including VCAM-1. This will eventually seed the invasion of GBM. 
CAMs play an important role in the interaction between the cells and ECM and 
are expressed on a variety of cells, including vascular endothelial cells (ECs) and 
tumor cells. One of the main components of ECM is hyaluronan (HA), which 
mediates cell attachment to other cells or ECM. The cell surface receptor for this 
molecule is CD44 that is believed to be a TIC marker [28]. CD44 has been 
implicated in the progression, adhesion and invasion of a variety of cancer types, 
including ovarian and GBM, and its depletion blocks GBM growth and sensitize 
GBM cells to cytotoxic drugs in vivo [25, 29].  HA is extruded to the extracellular 
space after being produced by Hyaluronan synthase (HAS) enzyme. HAS 
transcription is promoted by protein kinase C (PKC) which is activated by TNF-α. 
TNF-α can also indirectly promote the transcription of HAS. The binding of HA to 
the extracellular domain of CD44 receptor promotes the interaction between 
CD44 and the cytoskeletal proteins including ERM [30]. As it is also shown in 
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Figure 3, the downstream effects of TNF-α on PKC and HAS transcription 
eventually cause elevation of cell surface receptor CD44.  
Consequently increased expression of TNF-α increases the hyaluronan-CD44 
interactions, which in turn will increase the CD44–phosphorylated ezrin-radixin-
moiesin (ERM) family through PKC activation [31, 32]. The result of these 
interactions is the promotion of cell invasion, cell adhesion and cell motility 
through induction of cytoskeletal changes. These changes are induced by actin 
filaments that are joined to the cytoplasmic tail of CD44 via members of the ERM 
family [33].  
 
Research Overview 
In an effort to understand the mechanism underlying the GBM invasion, it is 
necessary to understand the role of cytokines, present and secreted in the tumor 
microenvironment by activated microglia. One of the main secreted cytokine by 
microglia is TNF-α. To that purpose, different migration assays are used to 
understand the effects of TNF-α on GBM dissemination by measuring the cell 
adhesion molecules as well as comparing the morphological changes cause by 
TNF-α. The cell adhesion molecules that are focused in this study are VCAM-1 
and CD44. The ICC protocol is followed to stain the migrated cells, and the 
experiment condition is kept constant through the entire experiment so that the 
images, taken by the confocal microscope, could be compared with each other. 
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In order to quantify the data, using Image-pro software the light intensity of the 
images are measured and using the Microsoft Excel, the light intensity of 80% of 
the pixels (Lum80) are calculated. The expression of different markers in 
response to TNF-α concentration was compared by comparing the Lum80 of 
each group.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Tissue Culturing 
Patient-derived glioma cell lines (PBT003;[34]) were maintained in DMEM/F-12 
medium supplemented with B27 (1:50), 1% L-Glutamine, 1M HEPES, 1% 
Pen/Strep and 1 mM Heparin Sodium solution. Cultures were supplemented with 
0.02 µg/mL of Epidermal Growth Factor (EGF) and 0.02 µg/mL of Fibroblast 
Growth Factor (FGF) every 3 days. Cultures were grown in 5% CO2 humidified 
incubator at 37°C and passaged every 3–5 days. Cells were ready for 
experiments when they reached 70% confluency.  
Working with low passage-number cells (less that 10) was considered as an 
important factor in this study. It was due to the fact that PBT003 cells had a 
tendency to adhere more to the surface by increasing the passage number. 
Therefore, to keep the cells in close passage numbers to each other between 
study replications, the cells were frozen down and new sets of cells were thawed 
several times. Therefore, in all biological replications the cells were in passage 
numbers 7-10.    
PBT003 cells were cryopreserved for long-term storage in liquid nitrogen. The 
cryopreservation protocol was as follow: cells were collected via centrifugation at 
1200 RPM for 5 minutes, followed by removing of the supernatant, using sterile 
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pasture pipette and then re-suspending the cell pellet in 1 mL of Non-enzymatic 
Cell Dissociation Solution (NECDS). The cells were then incubated for 5 minutes 
or until single cell suspension was reached, after which they were diluted in 
DMEM. Next the viability and density of the sample was determined by using the 
Nexcelom Cellameter Auto T4 cell counting machine. Then the cells were 
centrifuged for 5 minutes at 1200 RPM. The supernatant was then discarded and 
the cell pellet was re-suspended in cold cryopreservative medium at the final 
concentration of 106 cells/mL. Cryopreservative medium consisted of 10% 
dimethylsulfoxide (DMSO) and 90% fetal bovine serum (FBS). Then 1 mL of the 
cryopreservative medium containing 106 cells was added to the cryovials and 
immediatly placed in -20°C freezer for two hours, then transferred to -80°C 
freezer overnight, followed by  their long-term storage in liquid nitrogen. 
In order to thaw the cells, the cryovial containing PBT003 cells was placed into 
37°C water bath for about 30 seconds for quick thawing of the cells. While a 
small chunk of frozen cells still remain, the cryovials were removed from the 37°C 
water bath and the cells were transferred into media. The cells, diluted in the 
medium, were centrifuged for 5 minutes at 1200 RPM, the supernatant was 
removed, and the cells were re-suspended in the final medium in 106 cells per mL 
density and supplemented with EGF and FGF and grown in the incubator. 
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Boyden Chamber Cell Migration Assay 
The migration assay was performed using a transwell chamber system (24-well 
format; MilliPore, USA) with 8 µm pores. Following the schematic in Table 1, 
PBT003 cells were plated at the upper chamber, or both lower and upper 
chamber of the transwell chamber system. The cells were seeded at 106 cells in 
800 µL in the plate and 5×105 cells in 200 µL into the upper compartment of the 
insert. The medium containing the cells were placed in the upper chamber first, 
and then the lower chamber was field with the media. This was to avoid 
immediate mixing between the two chambers.  
 
Upper 
chamber Cells Cells Cells Cells Cells Cells Cells 
Lower 
chamber 
- 
(medium 
only) 
Cells HA Cells + HA TNF-α 
HA + 
TNF-α 
Cell + 
HA + 
TNF-α 
 
Table 1. The pattern followed in plating the cells in the Boyden chambers. Cells are plated 
in PBT003 medium in the upper chamber of all conditions to see their migration through the pores 
towards the different conditions in the lower chamber. The lower chamber were field with the 
medium supplemented with different conditions of TNF-α alone or in combination with HA or with 
the cells  
 
The cells in both chambers were seeded with 1.5% Matrigel to have all the cells 
attached to the surface and avoid formation of glioma spheres.  HA was used in 
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the lower chamber at 50 mg/mL, and TNF-α at 20 ng/mL. The chambers were 
then incubated at 37°C for 18 hours.  
 
Crystal Violet Staining of Migrated Cells 
After 18 hours of incubation, the inserts were removed from the plate and fixed 
with 95% ethanol for 30 minutes followed by washing with distilled water twice. 
The cells were then stained with 0.2% crystal violet for 30 minutes after which 
they were washed with distilled water three times. Then, using cotton swabs, the 
cells that were on the upper surface of the membrane were removed. Then the 
membrane was separated from the insert using a sharp pointed blade and placed 
on a slide. Using Prolong Gold mounting solution (Invitrogen), the membrane 
was fixed between the slide and the cover slip. The entire lower surface was then 
imaged by tilling the field using a 4x objective. Crystal violet stains nuclei dark 
purple, and the total number of migrated cells was counted by thresholding the 
nucleus color using ImagePro software. 
 
Dot Migration Assay 
The experiment starts when PBT003 cells were about 70% confluent after at 
least 4 to 5 days of being passaged with mostly tumor spheres suspended in 
culture rather than single cells. PBT003 cell spheres were centrifuged for 5 
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minutes at 1200 RPM. The pellet then was re-suspended in NECDS for 5 
minutes in a 37°C incubator or until a single cell suspension was approached 
after gentle trituration.  Cells were then re-suspended in DMEM/F12 medium and 
counted. Next PBT003 cells were centrifuged for 5 minutes at 1200 RPM and re-
suspended at range of 5 x 104 to 5 x 106 cell/mL. Then the cells were re-
suspended in DMEM/F12 medium supplemented with 3% BD Matrigel basement 
membrane matrix. 10µL of the cell suspension was taken (500-50,000 cells total) 
and plated as a dot on cover slips in 24-well plates. The cells were then placed in 
the incubator so they would attach to the cover slip. A minimum of one row of 
wells of the 24-well plate was filled with DMEM/F12 medium to keep the plate 
humid enough so that the 10 µL drop of the cells would not dry. After four hours 
of incubation, each well was filled with 500 µL of DMEM/F12 medium with 2.5-20 
ng/mL TNF-α plus 3% Matrigel. The number of the cells on cover slip and the 
study design is shown in Figure 4. M indicates that the row is filled with medium 
to keep the plate humid. The control population was filled with the same condition 
without TNF-α. After three days of incubation, the cells were fed with fresh 
medium having the same condition as in the beginning of the experiment. On day 
six of the experiment the cells were fixed and prepared for Immunocytochemistry 
(ICC).   
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Immunocytochemistry Analyses 
After six days of incubation, the cells were fixed with 500 µL of 4% 
Paraformaldehyde (PFA) in Tris-buffered saline (TBS) for 30 minutes at room 
temperature. After fixation, cultures were washed three times with wash solution 
(TBS + 0.1% Triton X-100) (Triton X-100 is used to permeabilize the cells), and 
then incubated with blocking solution (50% Western blocking reagent + 50% 
BlockAid (Invitrogen) solution + 1% Triton X-100) at room temperature for one 
hour. 
Then the blocking solution was replaced with the primary antibody solution 
(diluted in blocking solution). The primary antibody solutions used include; CD44, 
obtained from Abcam (USA), VCAM, obtained from R&D Systems (USA), and 
Ki67, obtained from Leica Biosystems (USA). The primary antibodies were 
diluted in 1:40, 1:200 and 1:100 respectively and incubated at 4°C overnight. The 
coverslips were then washed with washing solution three times and incubated 
with secondary antibody solution (diluted in blocking solution) in the dark at room 
temperature for two hours. The coverslips were then washed with washing 
solution three times and counterstained with Hoechst, diluted in washing solution, 
for 15 minutes. The coverslips were then washed and mounted in Prolong Gold 
antifade reagent. After two days at room temperature in the dark the cultures 
were ready for imaging. Figure 5 is the schematic illustration of these steps.  
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Figure 4. The study design to perform the dot migration assay on PBT003 cells. A) Cells are 
plated at different concentrations with different concentrations of TNF-α. Each plate has a 
minimum of one row of wells field with DMEM/F2 medium to keep the inside of the plate humid 
and avoid evaporation of the 10 µL cell bubble. M indicates the medium. B) the schematic of the 
cells plated in the experiment 
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Figure 5. Schematic of fluorescent ICC staining of PBT003 cells on coverslips.  
After six days of incubation, the cells are fixed, blocked and stained with primary and 
corresponding secondary antibody. Then, in order to stain the nucleus, the cells are stained with 
Hoechst solution and mounted on the slide using Prolong Gold. After being incubated in room 
temperature, slides are ready to be imaged. In this experiment the slides are imaged using Zeiss 
LSM 700 inverted confocal microscope 
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Imaging 
Images of the coverslips were taken using a Zeiss LSM 700 inverted confocal 
microscope, with tiling to image the entire culture. The cells were stained with 
secondary antibodies with fluorescent molecules that excite at 488, 555 and 647 
µm wavelengths. These secondary antibodies were made in donkey and were 
utilized to detect the Ki67, VCAM-1 and CD44 primary antibodies that were made 
in rabbit, goat and mouse respectively. The coverslips were then imaged with a 
10x objective (Zeiss Fluar 10x). 
All samples were imaged using standard configurations of the Zeiss Zen 
software. Pinhole size which prevents unwanted light to reach the detector was 
set to 1 Airy Unit (AU) for best compromise between depth discrimination and 
detection sensitivity.   
 
Time Lapse Imaging 
Using Zeiss AxioVision software in the Zeiss AxioObserver Z1 inverted 
microscope, a time lapse sequence of the dot migration assay was taken for the 
first three days of experiment. This microscope has a large heated enclosure, 
heated stage insert, and CO2 control. The cells survived for 3 days in the 
enclosed stage of the microscope, and tiled phase contrast images were taken 
from defined positions every 20 minutes. A movie of the cell movements was 
24 
 
made using ImagePro software. In this experiment the movements of the cells in 
control samples were compared to those treated with 20 ng/mL of TNF-α. 
 
Data Analyses 
All images in each experiment were taken with the same master gain, digital 
offset and digital gain settings. Therefore, changes in fluorescence intensity of 
the samples could be directly compared.   
Images were analyzed using the ImagPro software. Images were taken in 8 bit 
pictures resulting in 256 possible shades of color from 0 indicating as darkest 
and 256 as brightest. Fluorescence intensity was measured and transferred to 
Microsoft Excel. Zero intensity was considered as background and was 
eliminated from the calculations. The relative light intensity collected from each 
pixel was normalized by dividing the number of pixels expressing the same light 
intensity to the total number of collected pixels. This would provide the proportion 
of pixels. The cumulative probability showed the sum of number of the proportion 
of pixels that have light intensity below the measuring level. The cumulative 
probability of all data would eventually equal to 1 which means 100% of the data 
were covered. Next, the luminance density of 80% (Lum80) was calculated to 
show the light intensity of 80% of the pixels. Higher Lum80 indicates brighter 
pixels and therefore higher expression of the antigen. An illustration of the data 
analysis is shown in Table 2. 
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Expression (light 
intensity) 
Number of 
pixels 
Proportion of Light 
intensity 
Cumulative 
probability 
 (Background)  0   0 0 
1 A A / (A+B+C) = D D + 0 = G 
2 B B / (A+B+C) = E E + G = H 
3 C C / (A+B+C) = F F + H = I 
 
Table 2. An illustration on analyzing the fluorescence intensity of the stained ICC samples.  
 
 
Statistical Analyses 
The experiments were carried out in duplicate biological replication and data 
presented are representative of the independent experiments. Statistical 
significance was determined by the one way ANOVA with P value ≤ 0.05 as a 
threshold for significance. 
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CHAPTER THREE 
RESULTS 
 
The contributions of TNF-α to cell dissemination were investigated using different 
migration and invasion assays. To this end, a Boyden chamber migration assay 
was performed as the initial steps of the study.   
 
Boyden Chamber Migration 
The results of this study have shown that HA causes an increase in glioma cell 
migration across the insert membrane, whereas increased amounts of TNF-α 
significantly decreased glioma migration. Furthermore, migration of cells treated 
with HA + TNF-α is less than the control, as shown in Figure 6. Moreover, it is 
shown that HA and TNF-α caused morphological changes in the cells compared 
to the control population. It was observed that TNF-α treated cells were more 
adherent to each other than the non-treated control cells, which exhibited more 
flat and spread cell morphology, suggesting TNF-α is possibly effecting through 
signaling pathways that result in cell adhesion. 
     
Figure 6. The effects of TNF
chamber showed slight increase in the cell number but was not statistically significant. TNF
however, significantly decrease the number of cells migrated though the 8 micron pores. B) 
Morphology of the PBT003 cells with no treatment. It shows how the cells are flat and sprea
C) Shows the morphology of the cells after being treated with TNF
a pointy morphology and they have adhered to each other. (Measurements were made in 
triplicate in each of three independent experiments)
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Figure 7. Similarity of our experiment
same as in tumor environment, in which the GBM cells would move along with the blood vessels, 
the PBT003 cells move along with
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D). In this figure the control group (Figure 8, A and B) show the proliferation of 
the cells in a compact pattern whereas the treatment group with 20 ng/mL of 
TNF-α (Figure 8, C and D) shows the increased cell-cell adhesion and 
dissemination. The fluorescent images of dissemination in PBT003 cells treated 
with TNF-α is shown in Figure 9. In this figure, the VCAM-1 expression of the 
cells in the control non-treated cells (A) and in the cells treated with 20ng/mL of 
TNF-α for 6 days (B). In order to visualize the shape of the control sample and 
the dissemination pattern of the TNF-α treated cells, the brightness of both 
samples was increased to saturate the TNF-α treated cells.. The cells in the 
control group grew in a monolayer following the primarily dot shape, however, 
cells treated with TNF-α have migrated and made satellite-shaped secondary 
colonies. Furthermore, these cells have adhered to each other and disseminated 
toward different random directions.  
The number of satellite shaped secondary colonies that are made due to the 
effects of TNF-α are presented in Table 3. 
 
The Effects of TNF-α on VCAM-1 Expression in PBT003 Cells 
The expression of VCAM-1 and CD44 in different densities of GBM cells treated 
with different concentrations of TNF-α was measured using confocal microscopy. 
The preliminary results show an increase in the expression of both VCAM-1 and 
CD44 in GBM cells treated with TNF-α. 
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Figure 9 is a 6.40cm x 6.40cm image size for the control group (A) and 7.04cm x 
7.04cm image size for the treatment group (B) comparing the VCAM-1 
expression in PBT003 cells treated with 20ng/mL of TNF-α for six days. As is 
shown, the cells treated with TNF-α are brighter compared to control group 
meaning that the VCAM-1 expression in these cells is higher.  
In order to quantify the data, as described in Table 2, the light intensity of each 
pixel is measured using Image Pro software. Then the data is normalized to 
provide the proportion of light intensity. Figure 10 compares the proportion of 
light intensity of PBT003 cells treated with TNF-α and control. The magnified 
graph in part B of this figure indicates that higher number of pixels in control 
group express lower light intensity whereas more pixels express higher light 
intensity for TNF-α treated cells. Even though each pixel is not a representative 
of a cell (cells are much bigger) increased light intensity in higher portion of pixels 
indicate higher expression in that group. 
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Figure 8. Phase contrast imaging on PBT003 cells. Cell dissemination and adhesion can be 
seen in as short as 18 hours after TNF-α treatment. A) The control group after 18 hours of 
primary dot of cells is placed. B) The control group after 3 days of incubation. C) The treatment 
group after 18 hours of incubation with TNF-α. D) The same group as in C after incubation with 
TNF-α for three days  
 
 
A 
D 
B 
C 
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Figure 9. The effects of TNF-α on GBM dissemination. The image shows the VCAM-1 
expression of PBT003 cells initially seeded with 5x103 cells A) in the control, non-treated cells 
and B) in the cells treated with 20ng/mL of TNF-α for 6 days C, D and E are Further examples of 
GBM dissemination and satellite formation of PBT003 cells treated with 10ng/mL of TNF-α. The 
initial cell density is 5x106, 106 and 5x105 respectively. 
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Table 3. The number of satellite shape secondary colonies made as a result of TNF
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satellite colony was observed 
10ng/mL (X2), 5ng/mL 
20ng/mL, 10ng/mL(X2), 5ng/mL, 2.5ng/mL
20ng/mL (X2), 10ng/mL(x2), 2.5ng/mL
Nothing 
Nothing 
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In order to better compare the data, the cumulative probability of the proportion of 
pixels are measured as in Table 2. To illustrate, the pointer in Figure 11, points to 
the 0.8 cumulative probability of the control and treatment group. In this example, 
the 0.8 cumulative probability of the control population is close to 1 whereas this 
number in TNF-α treated population is close to 50, indicating that expression in 
cells treated with TNF-α is higher compared to control.  
 
 
Figure 11. Cumulative probability for VCAM expression in 106 PBT003 cells 
 
A method to compare the results would be to use the cumulative probability of 
the 0.8 data (Lum80). This means to compare the light intensity of 80% of 
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The Effects of Different Concentrations of TNF-α on VCAM-1 Expression of 
PBT003 Cells 
Increased concentration of TNF-α tends to significantly increase the expression 
of VCAM-1 in these cells (P value <0.0002). As is compared in Figure 12 the 
Lum80 of the cells treated with 20 ng/mL TNF-α is increased in all different cell 
densities compared to the control group. However, the increased expression of 
VCAM-1 in the group with 104 cells to begin with is higher compared to all other 
cell densities. Moreover, the group with lowest cell density to begin with, 500 
cells, has the lowest increase in the expression of VCAM-1 in response to TNF-α 
treatment. 
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Figure 12. The effects of increased TNF-α concentration on VCAM expression of PBT003 
cells. A) Increased TNF-α concentration caused increased expression of VCAM-1 in PBT003 
cells with all cell densities. C) The One-way ANOVA test result shows (P value <0.0002) 
significant increase in VCAM-1 expression in cells treated with all different concentrations of TNF-
α. 
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The Eeffects of TNF-α on VCAM-1 Expression of Different Densities of PBT003 
Cells 
The results of this experiment, shown in Figure 13, indicate that cell density could 
also be an important factor in invasion behavior of PBT003 cells. As 
demonstrated in this figure, although the overall trend of the graph is increased 
expression of VCAM-1 due to increased cell density, the group with initial density 
of 5x104 cells reached a plateau and did not show any more increase in VCAM-1 
expression. Furthermore, at 20ng/mL concentration of TNF-α, VCAM-1 
expression is decreased in groups with the initial seeding density of 5x104 cell, 
compared to the group with 104 cells initial density. 
 
   
Figure 13. The effects of different TNF-α concentrations on VCAM-1 expression of 
PBT003 cells in different densities 
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The Effects of TNF-α on CD44 Expression of PBT003 Cells 
PBT003 cells cultured at different densities are treated with different 
concentrations of TNF-α ranging from 2.5-20 ng/mL for six days. The results of 
this experiment showed an increase in the expression of CD44 in PBT003 cells 
in response to increased concentration of TNF-α. The detailed results are 
explained below: 
The Effects of Different Concentrations of TNF-α on CD44 Expression of PBT003 
Cells 
The results of this experiment are shown in Figure 14. PBT003 cells treated with 
20 ng/mL of TNF-α show significantly higher expression of CD44 compared to 
the control in all different cell densities (P value= 0.0013) Furthermore, in this 
experiment, the cells with the highest initial seeding cell number, 5x104 cells, 
show the most increase in CD44 expression compared to all other groups.  
Furthermore, the trend line of these graphs, shown in Figure 14B, show a dose 
dependent response in CD44 expression. 
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Figure 14. The effects of TNF-α concentration on CD44 expression on PBT003 cells. A) 
Increased concentration of TNF-α caused increased expression of CD44 in these cells. B) The 
trend line of these graphs show a dose dependent response in the increased CD44 expression. 
C) The One-Way ANOVA test on this experiment shows the increased expression of CD44 in 
response increased concentration of TNF-α is significant. (P values = 0.0013) 
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Following the same pattern seen in VCAM-1 expression, increased cell density 
caused an increase in CD44 expression. However, the control group did not 
show any significant increase in CD44 expression in response to increase in cell 
density (Figure 15). 
 
 
Figure 15. the effects of TNF-α on CD44 expression in different PBT003 cell densities 
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statistically significant.  According to Figure 16B, which shows the trend line of 
this experiment, the group of 104 initial cells treated with 20 ng/mL of TNF-α has 
positive trend of Ki67 expression in response to increased TNF-α concentration. 
Furthermore, this group shows rather fluctuating Ki67 levels in response to 
increased levels of TNF-α. The diverse form of this result is Figure 17 which 
shows the effects of cell density on Ki67 expression. As shown, increased cell 
density as an independent factor have cause increased cell proliferation in these 
cells.   
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Figure 16. The effects of TNF-α on Ki67 level in PBT003 cells. A) Increased concentration of 
TNF-α have caused decrease expression of Ki67 in the treated cells. B) The trend line for the 
graph is negative showing the decrease in all treated groups except the group with initially 104 
cells within which the Ki67 levels were fluctuating. C) The One-Way ANOVA data for these series 
of results showed that the decrease in the Ki67 is not significant (P value: 0.2313). The ANOVA 
test was also performed between the groups and none of the treated groups showed significant 
decrease compared to the control. 
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Figure 17. The effects of cell density on Ki67 levels of PBT003 cells. Regardless to the TNF-
α concentration used to treat the cells, the overall tendency of the cells was increased Ki67 levels 
in response to increased initial cell density. 
 
 
In that regard, focusing on the control group without any TNF-α treatment, shown 
in figure 18, it is clear that increased cell density alone could also cause an 
increase in the expression of Ki67.  
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Figure 18. The effects of cell density on Ki67 levels. 
 
 
The Effects of Cell Density on Tumor Dissemination 
Interestingly, the non-treated control group of PBT003 cells initially seeded at 
5x104 cells also showed satellites, resulted from tumor cell dissemination, after 
six days of incubation, emphasizing on the importance of the cell to cell 
interactions and the possible chemokines that are secreted as a consequence of 
these interactions. Figure 19 shows the VCAM-1 expression of representative 
image of control group seeded with 5x104 cells and incubated for six days.  
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Figure 19. The effects of cell density on tumor dissemination. The PBT003 control group that 
primarily seeded with 5x104 cells, disseminated to make a new tumor colony. 
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CHAPTER FOUR 
DISCUSSION 
 
One of the well-recognized associations in tumor studies is the link between 
cancer and inflammation [35] which was first noticed about 150 years ago when 
Virchow showed the tendency of cancer occurrence at sites of chronic 
inflammation [36]. In 2011, Weinberg for the first time talked about the six 
hallmark of the cancer [37] including evading growth suppression, activating 
invasion and metastasis, enabling replicative immortality, inducing angiogenesis, 
resisting cell death and sustaining proliferation signals. Later studies have shown 
the molecular pathways linking inflammation and cancer [38] which resulted in 
recognizing inflammation as the “seventh hallmark of cancer”. In the brain, 
inflammation occurs as a result of activation of microglia. TNF-α, which is 
involved in the regulation of cell survival and proliferation, may therefore, 
facilitate cancer development [23]. TNF-α can exert its effects directly or 
indirectly in cancer development through its interactions with inflammatory cells 
in the tumor microenvironment [23]. In this study we showed that TNF-α, 
increases the expression of cell adhesion molecules including VCAM-1 and 
CD44 (the receptor of hyaluronic acid) in GBM. Furthermore, we demonstrated 
that TNF-α diversely effects the GBM proliferation as Ki67 levels decreased by 
increased concentration of TNF-α. 
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The first observation of this study was about the GBM dissemination in response 
to TNF-α treatment. Figure 9, showing the primary observations after treatment, 
indicating that after six days of treatment with 20 ng/mL of TNF-α, GBM cells 
have increased their adherence and dissemination. In contrast with control group 
that has cells rather in monolayer, in the treatment group the cells have adhered 
to each other and disseminated in two different directions, making two new 
colonies. The direction of the colony appearance was random and did not follow 
any pattern.  
The next observation of this study was the increased expression of VCAM-1 in 
response to increased concentration of TNF-α (Figure 12). However, the two 
treatment groups with lowest initial cell number of 500 and 103, have shown 
decreased expression of VCAM-1 in response to treatment with 20 ng/mL of 
TNF-α in comparison to their response to 10 ng/mL of TNF-α. This suggest that 
cell density and TNF-α both play an important role in the adhesion of the cells. A 
possible explanation could be the fact that increased cell-cell interaction could 
cause secretion of different cytokines into ECM. Therefore, in all other groups, 
PBT003 cells that are initially seeded with 5x103 cell or more, secrete cytokines, 
possibly including TNF-α, which enhances the effects of added TNF-α on the 
cells. However, the groups with initial cell number of 500 and 103 have not had 
the required cell-cell interaction and eventually caused decrease in the VCAM-1 
expression. Interestingly, the most satellites were observed with samples treated 
with 10 ng/mL of TNF-α. And none of the low-density cells presented these 
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satellites. As a matter of fact, the effects of cell density in satellite formation was 
so significant that only the control group with the highest cell density (5x103) 
showed the presence of satellite (Figure 19). This repeatedly confirms the fact 
that cell-cell interaction in the seeded cells with high density possibly cause 
secretion of cytokines that effect the cell adhesion. Therefore the media on top of 
these cells are collected and preserved for further studies to see the amounts of 
different cytokines and chemokines present in the media of treated cells for three 
days.  
Studying the effects of cell density on VCAM-1 expression under constant 
concentrations of TNF-α, Figure 13 shows that, in overall, increase in cell density 
caused to an increase in VCAM-1 expression. However, all the treatment groups 
reached a plateau with highest initial cell number. This flat trend can be 
explained by the effects of TNF-α on Ki67 expression of these cells. As described 
in Figure 16, increased concentration of TNF-α decreases the proliferation rate of 
GBM. Therefore, cells with lower concentration of TNF-α proliferate more 
compared to the cells with higher concentrations. After six days of treatment, the 
cell density was not increased evenly in all samples which could explain the drop 
of VCAM-1 expression in cells treated with 20 ng/mL of TNF-α.  
Another interesting point in our results is the fact that TNF-α which is shown to 
cause increase in the level of adhesion molecules in GBM, causes decrease in 
the proliferation rate of this tumor cells. However, high proliferation rate is one of 
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the major causes of low survival rate in GBM. This confliction might be explained 
by the presence of multiple different cytokines and chemokines in the tumor 
microenvironment might overcome the negative effects of TNF-α on cell 
proliferation. Therefore, the next phase of this study will focus on in vivo analysis 
of the effects of TNF-α on the cells in mouse xenograft models. 
The end point of this study supports the hypothesis that TNF-α could positively 
effects the GBM invasion. However, the signaling pathway regulating the 
increased cell adhesion is still not clear. Therefore, the next step of this study 
would be to clarify whether TNF-α modulates its effects directly through its 
receptor or indirectly through activation of other molecules in the cells. To that 
end, one method would be blocking the TNF receptor associated factors (TRAF-
1 and TRAF-2) and another method would be blocking the present TNF-α in the 
culture by TNF-α neutralizing antibody. The results of either of these methods, 
alone or in combination, would give us more information and possibly confirm the 
results of this study. 
The possible downstream effects of TNF-α are through (a) activation of PI3K-
AKT and NF-κB pathway leading to VCAM-1 expression, or (b) phosphorylation 
of ERM through PKC activation which leads to increased HA expression and 
consequently CD44 expression. Each of these pathways alone or in combination 
could have caused the results seen in this study. Therefore, a next step in this 
study would be to clarify whether these two different pathways are working 
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independent from each other or related. A method to clarify this, would be 
blocking each of these pathways, NF-κB and PKC, separately and in together 
and treat the cells with TNF-α. Furthermore, CD44 and VCAM-1 could be the two 
possible target molecules to block. Blocking these two molecules could also 
confirm if the morphological changes shown in PBT003 cells treated with TNF-α 
are actually due to increased expression of VCAM-1 and CD44.   
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